Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Anti-VEGF-B agent CSL-346 developed to treat diabetic kidney disease

Feb. 14, 2017

No Comments

First patient dosed in Angion Biomedica's phase II study of BB3

Feb. 1, 2017

No Comments

Lundbeck discovers novel PDE9 inhibitors

Jan. 26, 2017

No Comments

Resverlogix reports results from phase I trial of apabetalone in severe kidney impairment

Jan. 24, 2017

No Comments

Roche divulges novel DDR1 inhibitors

Jan. 20, 2017

No Comments

Chongqing University reports PDE5A inhibitors

Jan. 13, 2017

No Comments

Kissei Pharmaceutical describes TRPM8 antagonists

Jan. 12, 2017

No Comments

Phase IIa study of SER-150 in diabetic nephropathy reaches primary endpoint

Jan. 5, 2017

No Comments

Ardelyx initiates two new trials of RDX-7675 for hyperkalemia

Jan. 5, 2017

No Comments

Vifor Pharma and ChemoCentryx expand kidney health alliance

Dec. 23, 2016

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Urology
RSS

Anti-VEGF-B agent CSL-346 developed to treat diabetic kidney disease

First patient dosed in Angion Biomedica's phase II study of BB3

Lundbeck discovers novel PDE9 inhibitors

Resverlogix reports results from phase I trial of apabetalone in severe kidney impairment

Roche divulges novel DDR1 inhibitors

Chongqing University reports PDE5A inhibitors

Kissei Pharmaceutical describes TRPM8 antagonists

Phase IIa study of SER-150 in diabetic nephropathy reaches primary endpoint

Ardelyx initiates two new trials of RDX-7675 for hyperkalemia

Vifor Pharma and ChemoCentryx expand kidney health alliance

Today's news in brief

Today's news in brief

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

Australia’s Celosia heads toward clinic with gene therapy for ALS

Sangamo stock plunges as Pfizer leaves hemophilia partnership

Urology RSS

Urology
RSS